Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review
Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress. Circulating tumor DNA (ctDNA) is a DNA fragment actively secreted by tumor cells or released...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-08-01
|
| Series: | Frontiers in Genetics |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fgene.2023.1172108/full |
| _version_ | 1827868245024047104 |
|---|---|
| author | Lemei Zhu Lemei Zhu Lemei Zhu Ran Xu Leilei Yang Wei Shi Yuan Zhang Yuan Zhang Yuan Zhang Juan Liu Juan Liu Juan Liu Xi Li Jun Zhou Jun Zhou Pingping Bing Pingping Bing |
| author_facet | Lemei Zhu Lemei Zhu Lemei Zhu Ran Xu Leilei Yang Wei Shi Yuan Zhang Yuan Zhang Yuan Zhang Juan Liu Juan Liu Juan Liu Xi Li Jun Zhou Jun Zhou Pingping Bing Pingping Bing |
| author_sort | Lemei Zhu |
| collection | DOAJ |
| description | Minimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress. Circulating tumor DNA (ctDNA) is a DNA fragment actively secreted by tumor cells or released into the circulatory system during the process of apoptosis or necrosis of tumor cells, which emerging as a non-invasive biomarker to dynamically monitor the therapeutic effect and prediction of recurrence. The feasibility of ctDNA as MRD detection and the revolution in ctDNA-based liquid biopsies provides a potential method for cancer monitoring. In this review, we summarized the main methods of ctDNA detection (PCR-based Sequencing and Next-Generation Sequencing) and their advantages and disadvantages. Additionally, we reviewed the significance of ctDNA analysis to guide the adjuvant therapy and predict the relapse of lung, breast and colon cancer et al. Finally, there are still many challenges of MRD detection, such as lack of standardization, false-negatives or false-positives results make misleading, and the requirement of validation using large independent cohorts to improve clinical outcomes. |
| first_indexed | 2024-03-12T15:28:11Z |
| format | Article |
| id | doaj.art-005c7f7c74d742f4858c3328dd872fcb |
| institution | Directory Open Access Journal |
| issn | 1664-8021 |
| language | English |
| last_indexed | 2024-03-12T15:28:11Z |
| publishDate | 2023-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Genetics |
| spelling | doaj.art-005c7f7c74d742f4858c3328dd872fcb2023-08-10T10:15:51ZengFrontiers Media S.A.Frontiers in Genetics1664-80212023-08-011410.3389/fgene.2023.11721081172108Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic reviewLemei Zhu0Lemei Zhu1Lemei Zhu2Ran Xu3Leilei Yang4Wei Shi5Yuan Zhang6Yuan Zhang7Yuan Zhang8Juan Liu9Juan Liu10Juan Liu11Xi Li12Jun Zhou13Jun Zhou14Pingping Bing15Pingping Bing16Hunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, ChinaAcademician Workstation, Changsha Medical University, Changsha, ChinaSchool of Public Health, Changsha Medical University, Changsha, ChinaGeneis Beijing Co., Ltd., Beijing, ChinaGeneis Beijing Co., Ltd., Beijing, ChinaGeneis Beijing Co., Ltd., Beijing, ChinaHunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, ChinaAcademician Workstation, Changsha Medical University, Changsha, ChinaSchool of Public Health, Changsha Medical University, Changsha, ChinaHunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, ChinaAcademician Workstation, Changsha Medical University, Changsha, ChinaSchool of Public Health, Changsha Medical University, Changsha, ChinaDepartment of Orthopedics, Xiangya Hospital Central South University, Changsha, ChinaHunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, ChinaAcademician Workstation, Changsha Medical University, Changsha, ChinaHunan Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha, ChinaAcademician Workstation, Changsha Medical University, Changsha, ChinaMinimal residual disease (MRD) refers to a very small number of residual tumor cells in the body during or after treatment, representing the persistence of the tumor and the possibility of clinical progress. Circulating tumor DNA (ctDNA) is a DNA fragment actively secreted by tumor cells or released into the circulatory system during the process of apoptosis or necrosis of tumor cells, which emerging as a non-invasive biomarker to dynamically monitor the therapeutic effect and prediction of recurrence. The feasibility of ctDNA as MRD detection and the revolution in ctDNA-based liquid biopsies provides a potential method for cancer monitoring. In this review, we summarized the main methods of ctDNA detection (PCR-based Sequencing and Next-Generation Sequencing) and their advantages and disadvantages. Additionally, we reviewed the significance of ctDNA analysis to guide the adjuvant therapy and predict the relapse of lung, breast and colon cancer et al. Finally, there are still many challenges of MRD detection, such as lack of standardization, false-negatives or false-positives results make misleading, and the requirement of validation using large independent cohorts to improve clinical outcomes.https://www.frontiersin.org/articles/10.3389/fgene.2023.1172108/fullMRDtumorCtDNAbiomarkerNGS |
| spellingShingle | Lemei Zhu Lemei Zhu Lemei Zhu Ran Xu Leilei Yang Wei Shi Yuan Zhang Yuan Zhang Yuan Zhang Juan Liu Juan Liu Juan Liu Xi Li Jun Zhou Jun Zhou Pingping Bing Pingping Bing Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review Frontiers in Genetics MRD tumor CtDNA biomarker NGS |
| title | Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review |
| title_full | Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review |
| title_fullStr | Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review |
| title_full_unstemmed | Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review |
| title_short | Minimal residual disease (MRD) detection in solid tumors using circulating tumor DNA: a systematic review |
| title_sort | minimal residual disease mrd detection in solid tumors using circulating tumor dna a systematic review |
| topic | MRD tumor CtDNA biomarker NGS |
| url | https://www.frontiersin.org/articles/10.3389/fgene.2023.1172108/full |
| work_keys_str_mv | AT lemeizhu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT lemeizhu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT lemeizhu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT ranxu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT leileiyang minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT weishi minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT yuanzhang minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT yuanzhang minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT yuanzhang minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT juanliu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT juanliu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT juanliu minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT xili minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT junzhou minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT junzhou minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT pingpingbing minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview AT pingpingbing minimalresidualdiseasemrddetectioninsolidtumorsusingcirculatingtumordnaasystematicreview |